Promising Dividend Stocks To Follow Now – July 31st

ProShares UltraPro Short QQQ, Chevron, and Novo Nordisk A/S are the three Dividend stocks to watch today, according to MarketBeat’s stock screener tool. Dividend stocks are shares of companies that regularly distribute a portion of their profits to shareholders, typically in the form of cash payments called dividends. Investors may favor them for generating income and potentially providing more stable returns, although dividend payments are not guaranteed and the stock’s value can still decline. These companies had the highest dollar trading volume of any Dividend stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Chevron (CVX)

Chevron Corporation, through its subsidiaries, engages in the integrated energy and chemicals operations in the United States and internationally. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, production, and transportation of crude oil and natural gas; processing, liquefaction, transportation, and regasification of liquefied natural gas; transportation of crude oil through pipelines; transportation, storage, and marketing of natural gas; and carbon capture and storage, as well as a gas-to-liquids plant.

Read Our Latest Research Report on CVX

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read Our Latest Research Report on NVO

Further Reading